Drugs With ‘Unsupported Price Increases’ Add $5bn To US Spending – ICER
Pharmaceutical Research and Manufacturers of America describes report as “flawed” and designed to advance the “false narrative that spending on medicines in increasing.”
You may also be interested in...
Revenue from migraine prophylaxis Aimovig shrank from Q2 levels, while cholesterol-lowering Repatha volume increased, but sales came in below consensus.
If nothing else, the purported draft may be a preview of what Democrats might do if they prevail in 2020. Proposal calls for HHS price negotiation, international reference pricing, price inflation rebates and structural Medicare Part D changes.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’